PRINCETON, N.J.--(BUSINESS WIRE)--Certara®, the global leader in model-informed drug development, regulatory science, market access and real-world evidence services, today announced the launch of ...

PRINCETON, NJ--(BUSINESS WIRE)--Certara®, the global model-informed drug development and decision support leader, today announced the launch of Phoenix® 8.2, the ...

In-silico bioequivalence approach using Simcyp’s Multi-Phase Multi-Layer Mechanistic Dermal Absorption model successfully replaced in-vivo, clinical studies in FDA ANDA approval PRINCETON, NJ – June ...

Certara, the global model-informed drug development and decision support leader, announced the launch of Phoenix 8.2, the industry gold standard in pharmacokinetic/ pharmacodynamic (PK/PD) modelling ...

RADNOR, Pa., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (CERT), a global leader in model-informed drug development, today announced the launch of Phoenix™ version 8.5. Phoenix is the ...

Certara, the leading provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, announced that it is partnering with Phase I Unit, ...

Unique capabilities expand the types of drugs, modalities, populations, and development questions modeled using the Simcyp PBPK Simulator Certara’s industry-leading Simcyp PBPK Simulator improves ...

Pharmaceutical biosimulation software company Certara won an R&D 100 Award from R&D World magazine for its its Simcyp COVID-19 Vaccine Model. The nearly 50-year-old worldwide competition lists the top ...

Background: Serdemetan is a compound that can cause replicative stress type responses in tumor cells and it has been administered to patients with solid tumors. ECG data from an ongoing first-in-human ...

Certara®, the global leader in model-informed drug development and regulatory science, today announced that its comprehensive influenza viral kinetic modeling review has just been published in Current ...

Certara provides scientists with automated, comprehensive tools for PK/PD analysis and modeling, and announces industry’s first PK/PD certification program for Phoenix software in partnership with ...

Bioavailability of the hedgehog pathway inhibitor GDC-0449 in a phase I pharmacokinetic (PK) study in healthy female subjects. Background: Serdemetan is a compound that can cause replicative stress ...